Monopar Therapeutics Inc. (NASDAQ:MNPR) Sees Large Increase in Short Interest

Monopar Therapeutics Inc. (NASDAQ:MNPRGet Rating) was the target of a significant increase in short interest in April. As of April 30th, there was short interest totalling 3,800 shares, an increase of 31.0% from the April 15th total of 2,900 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average trading volume of 6,000 shares, the short-interest ratio is presently 0.6 days.

Shares of Monopar Therapeutics stock traded up $0.17 during trading on Monday, hitting $2.02. 119 shares of the stock traded hands, compared to its average volume of 10,501. Monopar Therapeutics has a 52-week low of $1.70 and a 52-week high of $6.98. The stock’s fifty day simple moving average is $2.51 and its 200 day simple moving average is $3.26.

Monopar Therapeutics (NASDAQ:MNPRGet Rating) last posted its quarterly earnings data on Thursday, March 24th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). Analysts forecast that Monopar Therapeutics will post -1.01 earnings per share for the current year.

MNPR has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Monopar Therapeutics in a report on Friday, March 25th. Roth Capital reiterated a “buy” rating on shares of Monopar Therapeutics in a report on Thursday, March 24th. Finally, Zacks Investment Research upgraded shares of Monopar Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 18th.

A hedge fund recently raised its stake in Monopar Therapeutics stock. Geode Capital Management LLC boosted its position in Monopar Therapeutics Inc. (NASDAQ:MNPRGet Rating) by 36.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 39,171 shares of the company’s stock after acquiring an additional 10,410 shares during the quarter. Geode Capital Management LLC owned 0.31% of Monopar Therapeutics worth $189,000 at the end of the most recent quarter. Institutional investors and hedge funds own 1.62% of the company’s stock.

About Monopar Therapeutics (Get Rating)

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

Further Reading

Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with's FREE daily email newsletter.